pharmacie et médicaments – Myélome multiple - traitement et ASMR de la HAS

This written question concerns the treatment of multiple myeloma, a type of blood cancer, and the evaluation of the Added Value of Medical Services (ASMR) by France's High Authority for Health (HAS). It seeks clarification on the assessment process for new treatments. The question affects patients with multiple myeloma, healthcare professionals, and pharmaceutical companies involved in cancer drug development and assessment in France.